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Chronic exposure to elevated levels of glucocorticoids has been linked to age-related cognitive 44 
decline and may play a role in Alzheimer’s disease. In the brain, 11β-hydroxysteroid dehydrogenase 45 
type 1 (11β-HSD1) amplifies intracellular glucocorticoid levels. We show that short term treatment of 46 
aged, cognitively impaired C57BL/6 mice with the potent and selective 11β-HSD1 inhibitor UE2316 47 
improves memory, including following intracerebroventricular drug administration to the CNS alone. 48 
In the Tg2576 mouse model of Alzheimer’s disease, UE2316 treatment of mice aged 14 months for 4 49 
weeks also decreased the number of beta amyloid (Aβ) plaques in the cerebral cortex, associated with 50 
a selective increase in local insulin-degrading enzyme (involved in Aβ breakdown and known to be 51 
glucocorticoid-regulated). Chronic treatment of young Tg2576 mice with UE2316 for up to 13 52 
months prevented cognitive decline, but did not prevent Aβ plaque formation. We conclude that 53 
reducing glucocorticoid regeneration in the brain improves cognition independently of reduced Aβ 54 
plaque pathology, and that 11β-HSD1 inhibitors have potential as cognitive enhancers in age-55 











Glucocorticoids have long been recognised to impact on cognitive function, especially with aging (1-67 
3). Older individuals who exhibit learning and memory impairments have elevated glucocorticoid 68 
levels that parallel both cognitive deficits and shrinkage of the hippocampus, a key locus for memory 69 
formation. The hippocampus expresses a high density of corticosteroid receptors, both the lower 70 
affinity glucocorticoid receptor (GR) and the higher affinity mineralocorticoid receptor (MR), and 71 
these receptors are also abundant in other neocortical regions associated with cognition (4). Elevated 72 
glucocorticoid concentrations in vitro and in vivo promote biochemical, electrophysiological and 73 
structural changes in hippocampal neurons, which associate with poorer memory formation (5, 6). 74 
Manipulations which maintain low glucocorticoid levels from birth (neonatal programming) or mid-75 
life (adrenalectomy and low dose steroid replacement) prevent the emergence of cognitive deficits 76 
with age (7). 77 
Some patients with dementia, including those with Alzheimer’s disease (AD), have elevated 78 
circulating cortisol levels, which may contribute to AD pathogenesis (8, 9). It has been postulated that 79 
excess glucocorticoids increase levels of amyloid precursor protein (APP) and APP cleaving enzyme 80 
(BACE) leading to increased amyloid Aβ formation, reduced Aβ degradation via attenuation of 81 
insulin degrading enzyme (IDE) and increased tau expression (10). Other relevant glucocorticoid 82 
actions include hyperglycemia/insulin resistance, angiopathic and anti-angiogenic actions, increased 83 
excitatory (NMDA) neurotransmission and post-synaptic calcium signaling promoting neurotoxicity, 84 
metabolic endangerment of neurons and deleterious alterations in neuroimmune function (11). 85 
Glucocorticoid action via intracellular MR and GR is determined not only by circulating steroid levels 86 
but also by target tissue concentrations, modulated by intracellular metabolism by the isozymes of 87 
11β-hydroxysteroid dehydrogenase (11β-HSD) (12). The adult forebrain expresses 11β-HSD type 1, 88 
which catalyses conversion of inert 11-keto corticosteroids (cortisone, 11-dehydrocorticosterone) to 89 
active cortisol and corticosterone. 11β-HSD1 levels are increased in the aging rodent hippocampus 90 
and cortex and correlate with cognitive decline (13). Transgenic mice modestly overexpressing 11β-91 
HSD1 in the forebrain show premature memory decline with aging, while 11β-HSD1 null mice on 92 
two distinct genetic backgrounds, and even heterozygous null mice (with 50% less enzyme) resist 93 
cognitive decline with aging in a variety of tests (14). This protection associates with loss of the age-94 
associated rise in intrahippocampal corticosterone levels but without changing plasma corticosterone 95 
levels (13). 96 
Treatment of already aged mice with selective 11β-HSD1 inhibitors improves spatial memory 97 
performance. Effects are rapid, occurring within hours to days (15-17). Moreover, in small 98 
randomized placebo-controlled trials, the non-selective 11β-HSD inhibitor carbenoxolone improved 99 
memory in healthy aging men and in patients with type 2 diabetes (18). Whilst 11β-HSD1 inhibition 100 
improves glucose homeostasis and other metabolic parameters in obesity, metabolic changes were not 101 
correlated with cognitive effects in aged rodents or humans. These results support examination of 102 
selective 11β-HSD1 inhibitors in the treatment of age-related cognitive impairments. 103 
Here we examined a crucial issue, whether selective 11β-HSD1 inhibition alters cognition and 104 
pathology in AD. We used a murine AD model, the well-characterized Tg2576 mouse which bears a 105 
mutated human APP gene.  We generated and used UE2316, a novel and selective inhibitor of both 106 
human and rodent 11β-HSD1 with a low nanomolar IC50 value and high penetration into the brain 107 
(19,20). 108 
 109 
Materials and Methods  110 
UE2316 111 
UE2316 ([4-(2-chlorophenyl-4-fluoro-1-piperidinyl][5-(1H-pyrazol-4-yl)-3-thienyl]-methanone) was 112 
synthesized by High Force Ltd, UK according to methods previously described (21). In vitro 113 
screening of UE2316 potency in HEK293 cells stably transfected with hsd11b1 (22) showed a greater 114 
median inhibitory concentration (IC50) than our previously reported compound UE1961 (15, 20). 115 
Inhibition of 11β-HSD1 activity in tissue extracts was quantified as previously described (22). Liver 116 
brain and white adipose tissues were collected and snap frozen on dry ice. Frozen tissue (50-80mg) 117 
was homogenized in 700μl of chilled Krebs Buffer and a cleared homogenate prepared by 118 
centrifugation at 3500rpm for 5 minutes. The protein concentration of this homogenate was 119 
determined by Bradford assay.  For the assay, 25μl of 10mM NADPH was added to 250μg of the 120 
homogenate in a final volume of 200μl chilled Krebs buffer and incubated at 37°C for 20 minutes.  121 
3H-cortisone (25μl of 200nM) was then added and the assay incubated for a further 15 minutes prior 122 




H-cortisol conversion was determined in 123 
50μl of the defrosted reaction by capturing liberated 
3
H-cortisol on anti-cortisol (HyTest Ltd)-coated 124 
scintillation proximity assay beads (protein A-coated YSi, GE Healthcare). The percentage inhibition 125 




H-cortisol relative to that in tissue 126 
from vehicle treated mice. 127 
Animals 128 
All in vivo experiments were performed under a project license issued under the UK Scientific 129 
Procedures (Animals) Act, 1986, and with local ethical committee approval. Male C57Bl/6 mice were 130 
obtained from Harlan (UK). Male mice were chosen to eliminate the potential effects of gonadal 131 
hormonal fluctuations observed in females. Animals were group-housed under controlled lighting (on 132 
07.00-19.00h) and temperature (22°C), with access to food and water ad libitum. Experimental 133 
procedures are summarised in Table 1. 134 
For measurement of pharmacodynamic inhibition following oral administration, oral gavages with 135 
vehicle (38% PEG, 2% DMSO, 60% saline; Sigma, Poole, UK) or UE2316 dissolved in vehicle  were 136 
performed in the morning in animals aged 8-10 weeks (n=3 per dose). Animals were sacrificed post 137 
dosing (1, 4 and 6 hours) and the tissues retained for analysis of 11β-HSD1 inhibition. 138 
For assessment of pharmacodynamic inhibition following subcutaneous administration, C57Bl/6 mice 139 
(8-10 months, Harlan UK) (n=3 per group) were treated with either vehicle (50:50 DMSO: PEG, 140 
Sigma) or 10mg/kg/day UE2316 in vehicle via subcutaneously implanted Alzet osmotic minipumps 141 
(model 2004, Charles River, Margate, UK) for 14 days. Animals were sacrificed at this stage and the 142 
tissues retained for analysis of 11β-HSD1 inhibition. 143 
To show that the effects of UE2316 were not merely due to any peripheral metabolic actions of 11β-144 
HSD1 inhibition, the agent was administered intracerebroventricularly to aged male C57Bl/6 mice (24 145 
months, obtained from an in-house stock) were treated with either vehicle (artificial CSF; Alzet; 146 
Charles River) (n=9) or 100ng/h UE2316 in artificial CSF (n=8) administered via 147 
intracerebroventricular (icv) infusion, for 9 days, as previously described (23).  148 
For assessment of the effects of UE2316 on cognition in aging animals, aged male C57Bl/6 mice (22 149 
months, Harlan UK) were treated with either vehicle (n=6), 5mg/kg/day UE2316 (n=8) or 150 
15mg/kg/day UE2316 (n=8) in vehicle (50:50 DMSO: PEG, Sigma)  by subcutaneously implanted 151 
Alzet osmotic minipumps (model 2004, Charles River, Margate, UK) for 23 days, with body weights 152 
monitored at the start and end of the treatment. 153 
For the assessment of the effects of UE2316 in a model of AD, male Tg2576 (Hsiao et al., 1996) and 154 
age-matched genetic control (BL6;SJL) littermates were obtained from Taconic Europe (Ry, 155 
Denmark). Animals were singly housed due to aggressive behavior. In the short term treatment study, 156 
14 month old mice of each genotype (n=10 per group) were allocated at random to receive either 157 
UE2316 (10mg/kg/day) or vehicle (50:50 DMSO: PEG, Sigma) via 2 Alzet osmotic minipumps 158 
(model 2004) implanted subcutaneously to provide sufficient volume of drug or vehicle for 29 days. 159 
Food intake and body weight were monitored weekly throughout. For the long term study in which 160 
UE2316 was administered by incorporation in the diet, 6-7 month old Tg2576 male mice that were 161 
screened for eye color, coat color and rd1 homozygosity for the Pde6b
rd1
 retinal degeneration 162 
mutation by Taconic were fed with control diet (RM1) (n=16) or with RM1 containing 175 ppm 163 
UE2316 (for a calculated dosage of 30 mg/kg/day) (n= 32) (Special Diet Services, Broxburn, UK) for 164 
up to 57 weeks. Food intake and body weights were monitored weekly throughout the experiment and 165 
drug dosages were calculated based on average daily food intake. Each cohort of mice underwent 166 
repeated longitudinal cognitive testing.  167 
Behavior 168 
Mice were acclimatized to the behavior room for at least one hour before all procedures in order to 169 
minimize stress. All behavioral testing was conducted during the day between 9am and 12pm. 170 
Memory in passive avoidance 171 
Passive avoidance was assessed over 2 days (for aging studies in C57Bl/6 mice on days 13 and 14 172 
after the start of treatment, for the short term UE2316 study in Tg2576 mice on days 27 and 28 and at 173 
weeks 15 and 41 in the long term UE2316 Tg2576 study) in a step through light/dark box passive 174 
avoidance apparatus (Ugo Basile Comerio, VA, Italy) (13). On the first day, the latency to enter the 175 
dark compartment from the light compartment was measured, with the door to the dark compartment 176 
opening 30 seconds after the start of the trial. Twenty four hours later, the latency to enter the dark 177 
compartment was repeated, which was followed by a mild 0.3mA, 2 second foot-shock in the dark 178 
compartment. The mice were then retested 6 hours later for the latency to enter the dark compartment, 179 
this time without a foot-shock. The latencies were measured automatically by the device following the 180 
opening of the door separating the light and dark compartments with a maximal time allowed of 300 181 
seconds. Mice that did not enter the dark compartment were eliminated from analysis. 182 
Y maze 183 
Y maze testing of spatial hippocampal memory was performed as previously described with a 2 hour 184 
inter-trial interval (ITI) on day 10 following the start of treatment in the aged UE2316 study (15). For 185 
the UE2316 icv administration study, Y maze testing was performed on day 8 of treatment. The 186 
amount of time spent in each arm was measured and analyzed using AnyMaze software (Stoelting, 187 
Dublin, Ireland). 188 
Open field 189 
The open field test was performed on day 23 of the short term Tg2576 study and week 38 of the long 190 
term Tg2576 study. Mice were placed in an open field (OF) box (60 x60 cm) marked off into 16 equal 191 
squares. The outer row of squares adjacent to the walls of the box are considered less anxiogenic than 192 
the inner squares. For a 5 min period, the number of crossings, time, and distance (movement of all 193 
four legs into a new square) into each square was noted. Total movement in the maze reflects general 194 
activity and the relative movement in the inner zone is correlated to the anxiety state of the mouse. 195 
Spontaneous alternation 196 
Spontaneous alternation, a test of working hippocampal memory, was tested after 26 days of 197 
treatment in the short term treated Tg2576 mice and after 39 weeks of treatment in the long term diet 198 
study. Mice were placed in a Y maze apparatus consisting of three enclosed black Plexiglas arms (50 199 
cm long, 11 cm wide and 10 cm high), with prominent extramaze visual cues. Mice were allowed to 200 
explore the maze for five minutes after starting in a randomly chosen ‘start’ arm. The order and 201 
number of arm entries by each mouse in the 5 minute test period was recorded. Percentage 202 
spontaneous alternation was calculated using the following formula: % spontaneous alternation= 203 
[number of alternations (which is entries into 3 different arms consecutively)/(number of arms entered 204 
minus 2)] x 100. 205 
Morris water maze 206 
Morris water maze testing was performed as previously described on day 14 of the short term study 207 
and week 52 of the long term study (24). For the short term treatment study in Tg2576 mice, mice 208 
who did not swim (i.e. did not engage with the task) during the visible platform test, in which a visual 209 
cue (i.e. stacked Lego blocks) was placed on the submerged platform in the tank and no visuospatial 210 
clues were present (curtains were closed) were eliminated from analysis. The mice undertook 4 trials 211 
per day with a 20 minute inter trial interval and a maximum swim time of 90 seconds per trial for 4 212 
days. Latency, swim speed and the percentage of time spent in each quadrant of the pool were 213 
measured by Watermaze software (Actimetrics, Evanston, IL, USA). In the long term treatment study, 214 
mice were initially assessed after 12 months of treatment for their ability to engage in the visible 215 
platform test. In this instance, mice that were able to find the platform and improve their latencies 216 
after 2 days of 4 x 90 second trials  were then tested in the spatial water maze, in which the platform 217 
remained submerged without a visual cue on top and the mice utilised spatial clues located around the 218 
maze (curtains open). Mice were tested in 4 x 90 second trials per day over 6 days.  Twenty four 219 
hours after the final spatial water maze trial, the mice were then tested in the 90 second probe test, in 220 
which the hidden platform was removed from the tank and the percentage of time spent swimming in 221 
the target quadrant was measured. 222 
After behavioural testing, mice were sacrificed by cervical dislocation on day 29 of vehicle or 223 
UE2316 treatment in the short term study or after 44 and 57 weeks in the long term study. The brains 224 
were removed and hemisected coronally. One half of the brain was dissected and cortex, hippocampus 225 
and cerebellum were immediately frozen on dry ice and stored at -80°C for further analysis. The other 226 
half was fixed in 4% paraformaldehyde in PBS (4% PFA) (VWR, Lutterworth, UK) and 227 
cryoprotected in 30% sucrose (Sigma) overnight at 4°C before storage at -80°C for 228 
immunohistochemistry. 229 
Immunohistochemistry 230 
All immunohistochemistry was performed on free floating 25 µm sections stored at -20°C in 231 
cryoprotectant (50 mM phosphate buffer, 25% glycerol, 25% ethylene glycol, Sigma). Sections were 232 
transferred to a 12 well tissue culture plate with Netwell inserts (VWR) and washed in PBS. Antigen 233 
retrieval was performed by heating the sections in sodium citrate buffer, pH 6.0 (Sigma) at 95°C for 234 
15 minutes, followed by peroxidase treatment (1% H2O2 in PBS; Sigma) for 30 minutes to remove 235 
endogenous peroxidase activity, washed and then blocked with the appropriate serum for 1 hour 236 
followed by overnight incubation at 4°C with the antibody of choice. For staining using the 6E10 237 
antibody for visualization of amyloid beta plaques, the sections were blocked using the mouse on 238 
mouse (MOM) Ig blocking reagent (Vector Laboratories, Peterborough, UK) followed by overnight 239 
incubation with a 1:1000 dilution of beta amyloid 1-16 mouse monoclonal antibody (6E10) (Covance, 240 
Cambridge Bioscience, Cambridge, UK). Following washing, sections were incubated with secondary 241 
antibody for 1 hour at room temperature.  Staining was visualised using the Vectastain ABC kit and 242 
DAB peroxidase substrate kit (Vector Laboratories). The sections were then mounted on Superfrost 243 
Plus slides (VWR), dehydrated and coverslipped. The number of 6E10 positive plaques per brain area 244 
was counted by an experimenter blinded to the treatment group using a Zeiss Axioskop and the 245 
KS300 imaging program (Zeiss, Eching, Germany). Plaque area, measured using the same program, 246 
was expressed as plaque area divided by the total area of the brain region. Iba-1 antibody was 247 
purchased from Abcam (Cambridge, UK). Goat and rabbit serum were purchased from Sigma. 248 
Biotinylated rabbit anti-goat IgG antibody and biotinylated rabbit anti-sheep IgG antibody were 249 
purchased from Vector Labs. 250 
Western blotting 251 
Protein extracts were prepared from brain areas by homogenization in Krebs buffer containing 252 
protease inhibitor (Roche, Burgess Hill, UK) followed by centrifugation at 3000 RPM for 5 minutes. 253 
Protein concentration of the supernatant was measured using the Bradford Assay (BioRad, Hemel 254 
Hempstead, UK). Proteins were separated by SDS-PAGE using NuPAGE Novex 4-12% bis-tris gels 255 
(Invitrogen, Paisley, UK) and transferred to nitrocellulose membranes (0.2µm pore size; Invitrogen). 256 
Membranes were blocked for 1 hour at room temperature in 5% non-fat dry milk blotting grade 257 
blocker (BioRad) in PBS, pH 7.4, containing 0.1% Tween 20 (PBS-T) and then incubated overnight 258 
with shaking at 4°C with the primary antibody diluted in blocking reagent. This was followed by 259 
incubation at room temperature in the appropriate secondary antibody. IDE, PSD95, ADAM10, 260 
synaptophysin and CD31 antibodies were purchased from Abcam. The anti-BACE 1 N terminus (46-261 
62) antibody was sourced from Sigma. Mouse beta-tubulin antibody was purchased from Merck-262 
Millipore (Watford UK). Goat-anti rabbit IgG antibody was obtained from Licor Biosciences UK 263 
(Cambridge UK). Alexa Fluor 680 donkey anti-sheep IgG (H+L) and Alexa Fluor 680 rabbit anti-goat 264 
IgG antibodies were purchased from Invitrogen (Paisley, UK). Proteins were visualized and band 265 
intensities were quantified using the Odyssey Infrared Imaging System (LiCor Biosciences UK, 266 
Cambridge, UK). 267 
Statistical analysis 268 
Data are expressed as mean + SEM. Groups were compared by ANOVA. When ANOVA was 269 
significant post hoc tests were performed as indicated in the Figure legends. Differences were 270 
considered significant when p<0.05. 271 
Results 272 
UE2316 inhibits 11β-HSD1 in the brain 273 
We previously reported the discovery and pharmacological effects of the selective 11β-HSD1 274 
inhibitor UE1961, which was based on a thiophene amide scaffold (15). However, this molecule has 275 
sub-optimal potency and pharmacokinetic properties for progression to late-stage preclinical 276 
development. Further medicinal chemistry optimisation of this compound, replacing the 277 
decahydroquinoline and substituted piperidine groups flanking the thiophene core, led to the 278 
identification of UE2316 (Figure 1A). UE2316 displays greater potency than UE1961, excellent 279 
selectivity and an improved drug metabolism and pharmacokinetic profile for use in in vivo studies 280 
(Figure 1B). Pharmacodynamic inhibition of 11β-HSD1 in tissues was confirmed following 281 
administration by oral and subcutaneous (SC) routes. Single dose oral administration of UE2316 to 282 
C57BL/6 mice induced significant ex vivo inhibition of 11β-HSD1 in the brain for at least 4 hours 283 
(Figure 1C), while constant infusion of 10mg/kg/day of UE2316 over 14 days by SC Alzet osmotic 284 
minipumps also produced 34.2 ± 8.3 % inhibition of 11β-HSD1 in the brain (data not shown). The 285 
results from these studies were in agreement with those from previous studies (19,20). UE2316 was 286 
thus chosen to investigate the effects of chronic 11β-HSD1 inhibition on cognitive impairment and 287 
AD pathology in mouse models using either SC or oral administration. 288 
UE2316 acts in the brain to improve cognition in aged wild type mice 289 
To assess the effects of UE2316 on memory in cognitively impaired mice, C57BL/6 male mice aged 290 
22 months were randomly assigned to treatment with 0, 5 or 15 mg/kg/day of UE2316 via SC 291 
implanted Alzet minipumps for 14 days. In the Y-maze, a non-stressful test of hippocampal-292 
associated spatial memory, there was a significant increase in time spent exploring the novel arm after 293 
a 120 min inter-trial interval in mice receiving 15 mg/kg/day UE2316 compared to vehicle-treated 294 
controls (Figure 2A). Cognition was also assessed in the passive avoidance task, which tests 295 
emotional and fear associated memories (13). During the retention phase of the passive avoidance 296 
test, UE2316 increased latency to enter the dark compartment at both5 and 15 mg/kg/day compared 297 
with vehicle-treated mice, indicating improved memory (of the footshock) (Figure 2B). 298 
To investigate whether brain-specific inhibition of 11β-HSD1 was responsible for these improvements 299 
in cognition, we delivered UE2316 directly to the brain of aged (24 month old) C57BL/6 mice at an 300 
appropriate concentration via icv administration for 9 days. Post-mortem analysis of whole brain 301 
samples revealed 39.9 ± 5.5 % inhibition of 11β-HSD1 was achieved with a 100 ng/h infusion. 302 
Vehicle-treated aged controls showed impaired spatial memory in the Y maze (similar times spent in 303 
all 3 arms) as previously reported (15). Mice treated with icv UE2316 spent more time exploring the 304 
novel arm of the Y-maze than vehicle-treated mice, indicating an improvement in spatial memory 305 
after 8 days of treatment (Figure 2C). 306 
UE2316 improves cognition in a murine model of Alzheimer’s disease 307 
Following confirmation of the effects of 11β-HSD1 inhibition using UE2316 in age-related cognitive 308 
impairment, we examined effects of short-term UE2316 administration in the Tg2576 mouse model of 309 
AD. Tg2576 mice carry a transgene with mutations at amino acids 670 and 671 in the human APP 310 
gene under the control of the hamster prion promoter, which leads to accumulation of Aβ plaques in 311 
the brain from 9-12 months of age with consequent cognitive impairment (25). Singly housed age-312 
matched male mice were separated into 4 groups of 10 mice per group: wild type or Tg2576 mice 313 
administered vehicle or UE2316. Mice were treated by 2 SC implanted Alzet minipumps from 14 314 
months of age for 29 days. No treatment-related adverse effects on final body weight, daily food 315 
intake or adrenal size were observed. However, as previously reported, Tg2576 mice weighed less 316 
than their wild type littermates throughout the study despite consuming more food (Supplementary 317 
Figure 1A-B) , which may reflect their increase in locomotor activity and hypothalamic dysfunction 318 
(26,27). 319 
Tg2576 mice perform poorly in the Y-maze spatial memory test due to retinal degeneration, therefore, 320 
fear-associated memory was assessed in the passive avoidance task, which is not dependent on visual 321 
acuity. In this test, performed on days 27 and 28 of drug or vehicle administration, UE2316 treatment 322 
increased latencies in re-entry to the dark compartment at 6 hours post footshock in both control and 323 
Tg2576 mice (Figure 3A), suggesting an improvement in fear associated memory with drug treatment. 324 
The effect of UE2316 treatment was particularly pronounced in Tg2576 mice, which may reflect a 325 
difference in sensitivity to the electrical shock in this mouse strain. In a separate open field test, no 326 
difference was observed in the time spent in the inner zone in either wild type or Tg2576 mice with or 327 
without drug (two way ANOVA, treatment effect: p=0.98), suggesting that UE2316 does not affect 328 
anxiety (Figure 3B). No difference in speed was observed between either strain, in the presence or 329 
absence of drug (two way ANOVA, treatment effect: p=0.94, data not shown). 330 
In spontaneous alternation, a test of working hippocampal memory, Tg2576 mice tended to enter 331 
more arms than the control mice (p=0.06), which again may be due to their increased locomotion 332 
(data not shown) (26). Treatment with UE2316 led to a trend in increased percentage alternation in 333 
both wild type and Tg2576 mice compared to vehicle (two way ANOVA, treatment effect: p=0.06) 334 
(Figure 3C).  335 
UE2316 prevents cognitive decline in a murine model of Alzheimer’s disease 336 
Effects of long-term UE2316 treatment were examined by administering UE2316 in the diet to 6-7 337 
month old Tg2576 mice over a period of 57 weeks. The mice on the UE2316-supplemented diet 338 
maintained an average daily dose of approximately 30 mg/kg/day throughout the experiment and did 339 
not exhibit any adverse effects (Supplementary Figure 2A). UE2316-treated mice tended to weigh less 340 
than vehicle-treated mice up to 44 weeks (ANOVA, p<0.01) despite eating more food (ANOVA, 341 
p<0.001) (Supplementary Figure 2B-C). In contrast to the short-term study, mice were pre-screened 342 
for retinal degeneration (RD) and only those which were RD negative were included. Memory was 343 
assessed at intervals using passive avoidance, spontaneous alternation and Morris Water Maze tests. 344 
Fear associated memory was assessed using the passive avoidance test after 15 and 41 weeks of 345 
treatment. As expected, at 15 weeks, when mice were aged 10-11 months, similarly increased 346 
latencies were observed following training in both the vehicle and UE2316-treated groups, consistent 347 
with preserved cognitive function at this age (Figure 4A). In contrast, after 41 weeks of treatment, 348 
when the mice were aged 16-17 months, vehicle-treated mice exhibited cognitive impairment as 349 
demonstrated by lack of prolongation of latency after training, but Tg2576 mice treated with UE2316 350 
maintained an increase in latency to enter the dark compartment 6 hours post shock, indicating that 351 
UE2316 prevents an age-associated decline in fear associated memory (Figure 4B). There was an 352 
increase in latency for training in vehicle-treated mice, suggesting an impairment in their ability to 353 
effectively to engage with the task. No difference in anxiety was observed with UE2316 treatment in a 354 
separate open field test (two way ANOVA, treatment effect: p=0.25), but Tg2576 mice were less 355 
anxious compared to wild type mice (two way ANOVA, genotype effect: p<0.01) (Figure 5A). There 356 
was also an increase in locomotion in Tg2576 mice when compared to wild type mice (two way 357 
ANOVA, genotype effect: p<0.01), but no effect of treatment (two way ANOVA, treatment effect: 358 
p=0.69). 359 
Working memory was assessed at 39 weeks of treatment using the spontaneous alternation test. 360 
UE2316 increased spontaneous alternation (Figure 5B), although there was no difference in the total 361 
number of arm entries (data not shown). 362 
Spatial memory was assessed in the Morris Water Maze after 52 weeks of treatment (mice aged 18-19 363 
months). Swim speeds were not affected by UE2316 treatment and there was no difference between 364 
strains (data not shown). UE2316 reduced the time taken to find the hidden platform across the testing 365 
period (Figure 5C), and increased time spent in the target quadrant during the probe test performed 24 366 
hours after the final trial (vehicle: 34.2±3.2%, UE2316: 52.1±5.1%, p=0.02), consistent with 367 
improved spatial learning and retention (Supplementary Figure 3A). 368 
Effect of UE2316 on Aβ plaques in the brain 369 
Immunohistochemistry with 6E10 antibody (28), which detects Aβ1-16, was performed on Tg2576 370 
brains to determine whether UE2316 affected the number and volume of Aβ plaques (wild type 371 
control brains were not analysed as these mice do not develop amyloid plaques) (Figure 7A). 372 
Short-term 4-week UE2316 treatment decreased Aβ plaque number in the cortex and amygdala but 373 
not the hippocampus of 15m old Tg2576 mice (Figure 6A). The total plaque number in the brains of 374 
Tg2576 mice was 54% lower in UE2316-treated than vehicle-treated mice. Plaque areas were 375 
correspondingly reduced (Figure 6B). 376 
After chronic 44-week treatment with UE2316 (mice aged 17-18 months) there were a similar number 377 
of Aβ plaques in the cortex and hippocampus as in mice treated with UE2316 for only 4 weeks 378 
(Figure 6C). However, there were fewer Aβ plaques in the brains of the vehicle-treated group from 379 
the 44-week study than in the vehicle-treated animals from the 4-week study. In the 44-week study 380 
there was no significant effect of UE2316 on number of Aβ plaques. 381 
To explore possible mechanisms mediating the effects of short-term UE2316 treatment on Aβ plaque 382 
burden in the cortex we conducted western blot analyses of selected proteins involved in Aβ 383 
generation and metabolism, the expression of which are known to be regulated by glucocorticoids 384 
(Figure 7B). UE2316 treatment did not modulate BACE protein expression in either WT or Tg2576 385 
mice (Table 2). Nor did UE2316 alter ADAM10, a metalloproteinase possessing α-secretase activity 386 
involved in the non-amyloidogenic pathway of APP processing (29) (Table 2). However, UE2316 387 
significantly increased, by 31% and 34% respectively, insulin degrading enzyme (IDE) protein 388 
expression in the cortex of both control and Tg2576 mice (Table 2). No difference in IDE expression 389 
was found in the brains from mice treated with UE2316 for 44 weeks (IDE to beta-tubulin ratio: 390 
vehicle: 0.016 + 0.004 vs UE2316: 0.011 + 0.002; Student’s t-test, p=0.22). 391 
PSD95 and synaptophysin, markers of synaptic density (30,31), were unaffected by UE2316 (Table 392 
2). In addition, microglial density was not increased as evidenced by no change in Iba1 levels (32) 393 
(Table 2). CD31 staining was also conducted to probe for potential changes in cerebral vascular 394 
density, as 11β-HSD1 null mice exhibit enhanced angiogenesis (33), but no effect of UE2316 was 395 
observed (Table 2). 396 
 397 
Discussion 398 
We have generated UE2316, which is a potent and selective inhibitor of 11β-HSD1 in mouse brain. 399 
UE2316 administered either systemically or directly to the brain induces improvements in memory in 400 
cognitively impaired rodents. In aging mice the effects of UE2316 recapitulate those of other selective 401 
11β-HSD1 inhibitors (15, 16) and provide further evidence that short term inhibition of 11β-HSD1 in 402 
the brain improves memory impairments associated with aging. Moreover, our data demonstrate that 403 
these improvements are associated with inhibition of 11β-HSD1 specifically in the brain since mice 404 
treated with icv administration with sub-systemic doses display memory improvements comparable to 405 
those observed in mice treated systemically. The effects are evident across a range of behavioral tasks 406 
that involve the hippocampus, in contrast with the attenuation of contextual fear-associated memory 407 
that we previously reported with UE2316 which is likely mediated in different brain regions (19). It is 408 
likely that these short term improvements in memory are due to the effects of reduced intracellular 409 
corticosterone in regions of the brain such as the hippocampus, which are sufficient to reverse the 410 
memory-impairing effects of glucocorticoids in aged mice (17). Structural changes to the 411 
hippocampus, such as synaptic and dendritic atrophy may be reversed by reduced intracellular 412 
glucocorticoid levels over a period of hours and weeks respectively, and could be responsible for the 413 
short term memory improvements observed in these studies (34,35). However, we also observed 414 
significant improvements in memory with long term 11β-HSD1 inhibition which may be mediated by 415 
structural hippocampal changes. It should be noted that behavioral testing was only carried out in 416 
male mice and the exploration of any potentially sexually dimorphic effects of 11β-HSD1 inhibition 417 
will require separate, comparative studies in male and female mice.  418 
There is now substantial evidence from studies in rodents and in humans that reductions in 11β-HSD1 419 
activity in the brain provides beneficial effects on the cognitive decline associated with aging (15, 16, 420 
18, 23). However, to date no studies have been published that assess the effects on 11β-HSD1 421 
inhibition in rodent models of AD. We found that short term (29 days) treatment of already 422 
cognitively-impaired 14-month old Tg2576 mice with UE2316 led to improvements in memory 423 
during the passive avoidance task. UE2316 also improved latency in wild type mice but to a lesser 424 
extent than in Tg2576 mice. Our data also demonstrate that long term inhibition of 11β-HSD1 in 425 
Tg2576 mice maintains cognitive performance with aging since age-matched mice without UE2316 426 
treatment are cognitively impaired in tests performed from 16 months of age onwards. Moreover, 427 
cognitive improvement with 11β-HSD1 inhibition is maintained in the presence of significant 428 
Alzheimer’s pathology. 429 
In the Tg2576 mouse strain, Aβ plaques have been shown to develop from 9 months of age onwards, 430 
associated with impairments in cognitive ability in memory tests from 10-12 months (25). As 431 
expected, when we examined the brains of the Tg2576 mice Aβ plaques were observed in the cortex, 432 
amygdala and hippocampus. Short term UE2316 treatment substantially decreased Aβ plaque number 433 
and area in the cortex and amygdala of Tg2576 mice. In contrast, in a separate cohort of mice from 434 
which those with retinal impairment were excluded, we observed less Aβ plaque burden and no 435 
statistically significant effects of chronic UE2316 administration. This likely reflects the differences 436 
in animals with and without visual impairment. Overall, the results suggest that treatment with 437 
UE2316 has a disease-modifying effect on amyloid plaque deposition in Tg2576 mouse brains by 438 
impairing plaque accumulation. However, our findings dissociate cognitive improvement from Aβ 439 
plaque pathology after chronic treatment, suggesting the mechanism of improved cognition with 11β-440 
HSD1 inhibition is not mediated solely through reduced plaque burden. Whatever the mechanism, the 441 
effect on cognition is likely associated with lowered intracellular glucocorticoid levels in the brain, 442 
and the consequent altered balance of glucocorticoid and mineralocorticoid receptor action (23). 443 
Additionally, we observed an increase in cortical IDE protein levels with short term UE2316 444 
treatment. This increase may explain, in some part, the reduction in plaque numbers and plaque area 445 
in the drug-treated mice, as previous studies have demonstrated that overexpression of IDE or 446 
neprilysin in the neurons of transgenic mice significantly reduced brain amyloid beta levels and 447 
slowed or completely prevented amyloid plaque formation in APP TG mice (36), while IDE null mice 448 
have excess cerebral accumulation of Aβ (37). In humans, genome-wide association studies report a 449 
higher susceptibility to AD in Finnish patients with polymorphisms of IDE, suggesting that the rate of 450 
Aβ degradation may be an important factor in the development of human AD (38). However, the lack 451 
of IDE induction with chronic UE2316 administration, in the face of persisting benefits for cognitive 452 
function, suggests that other pathways are involved in cognitive protection with 11β-HSD1 inhibition. 453 
Alternatively, Tg2576 mice selected for intact vision may be relatively resistant to glucocorticoid 454 
effects on IDE and Aβ turnover. 455 
These pre-clinical results support the concept that 11β-HSD1 inhibition may be efficacious for 456 
memory impairments not only with aging, but also in AD. A recent phase 2 clinical trial in patients 457 
with mild-moderate AD was halted, however, when the selective 11β-HSD1 inhibitor ABT-384 failed 458 
to show non-inferiority against donepezil for the primary endpoint of ADAS-Cog score (39). 459 
Although a pharmacodynamic study of ABT-384 using stable isotope d4-cortisol tracer has been 460 
reported (40), it remains uncertain whether ABT-384 inhibited 11β-HSD1 adequately in brain since: 461 
data were presented for only two control subjects without administration of ABT-384; after ABT-384 462 
administration, d3-cortisol levels (generated by 11β-HSD1) (41) were very low in plasma, consistent 463 
with systemic enzyme inhibition, and this may account for the undetectable levels of d3-cortisol in 464 
CSF; and the maximum CSF concentrations of ABT-384 achieved, which were present for only a 465 
short time after dosing, were not high enough to inhibit 11β-HSD1 by more than 10%, according to 466 
published potency of the compound. The benefits of 11β-HSD1 inhibition may only be apparent in the 467 
treatment of early disease, when the combination of symptomatic cognitive improvement and 468 
potential for disease modification we have observed in the mouse model of AD may be most useful. 469 
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 593 
Tables. 594 
Table 1: Treatment table. 595 
Table 2: UE2316 increased IDE protein levels in the cortex of control and Tg2576 mice. Data are 596 
mean ± SEM from Western blot densitometry, normalized to beta-tubulin. 2-way ANOVA analysis 597 
was performed and the treatment effect of UE2316 is shown. For IDE *p<0.04 for effect of UE2316 598 
within each genotype by post hoc Fisher’s LSD tests. 599 
 600 
Figures and Legends. 601 
Figure 1: UE2316 Characteristics. A: Structural comparison of UE1961 and UE2316 B: Potency 602 
and selectivity of UE2316. C: Male C57BL6 mice were treated with a single 10 mg/kg oral dose of 603 
UE2316 (n=3 animals per time point) and inhibition by scintillation proximity assay was assessed 1, 4 604 
and 6 hours post dosing and expressed as % inhibition compared with values obtained in vehicle-605 
treated mice. (One-way ANOVA, p=0.009; Bonferroni’s post-hoc comparisons, *p<0.05 vs vehicle). 606 
Figure 2: UE2316 improved spatial and fear-associated memory in aged C57Bl6 mice. Aged 22 607 
month-old C57Bl6 mice were treated with 0 (n=6), 5 (n=8) or 15 (n=8) mg/kg/day UE2316 for 23 608 
days via SC implanted osmotic minipumps. A: Spatial memory was assessed by Y maze on day 10 of 609 
treatment. The initial 1 minute ITI was performed prior to surgery. Treatment with 15 mg/kg/day 610 
UE2316 increased the time spent in the novel arm in the 2 hour ITI compared to vehicle treated 611 
animals (*p<0.05 by Student’s t-test with Bonferroni correction), and a trend for improvement was 612 
seen with the 5 mg/kg/day dose. B: Passive avoidance was analyzed on days 13 and 14 of treatment. 613 
Both 5 mg/kg/day (*p=0.02 vs vehicle by Student’s t-test) and 15 mg/kg/day (*p=0.03 by Student’s t-614 
test) UE2316 improved latency in the retention trial compared to the vehicle treated group (by two-615 
way repeated measures ANOVA drug interaction with training vs retention p<0.05). C: Similarly aged 616 
C57Bl/6 mice were treated with an infusion of either vehicle (artificial CSF) (n=9) or 100ng/h 617 
UE2316 (n=8) via ICV cannulas. Spatial memory was assessed by Y maze on day 9 of treatment. The 618 
initial 1 minute ITI was performed prior to surgery. Treatment with UE2316 increased the time spent 619 
exploring the novel arm during the 2 hour ITI compared with vehicle-treated controls (**p=0.005 by 620 
Student’s t-test). 621 
Figure 3: UE2316 improved fear-associated behaviour in the passive avoidance test in Tg2576 622 
mice. Tg2576 and wild type mice (n=10 per group) were treated with vehicle or UE2316 at 10 623 
mg/kg/day by SC Alzet minipump infusion from the age of 14 months for 29 days. A: Tg2576 mice 624 
were assessed in the passive avoidance task on days 27 and 28 of drug treatment. The latency to enter 625 
the dark compartment was assessed in the training trial (pre) and the retention trial (post). UE2316 626 
increased latency to enter the dark compartment 6 hours post shock (2-way repeated measures 627 
ANOVA drug effect p<0.04; **p<0.01 by Student’s t test) to a greater extent in Tg2576 mice (by an 628 
increment of 171.6 + 28.0 seconds compared to 42.6 + 21.5 seconds in vehicle-treated mice, 629 
**p=0.004 by Student’s t-test). B: Open-field was performed after 23 days of treatment in vehicle and 630 
UE2316 treated wild type and Tg2576 mice.  The percentage of time during the 5 minute trial that 631 
was spent in the inner zone of the open field apparatus was measured. There was no significant effect 632 
of treatment or genotype. C: Spontaneous alternation was assessed at day 26 of treatment. There was a 633 
trend for increased alternation with UE2316 treatment (2-way ANOVA; treatment: p=0.06). 634 
Figure 4: Long term administration of UE2316 improves cognition in Tg2576 mice. Tg2576 mice 635 
were treated with either control diet (RM1, n=16) or RM1 supplemented with 175 ppm UE2316 for 636 
an estimated dose of 30 mg/kg/day (n=32) from the age of 6- 7 months for 57 weeks. A: Passive 637 
avoidance was analysed after 15 weeks of treatment with vehicle (n=13) or UE2316 (n=23). Both 638 
groups exhibited significantly increased latency to enter the dark compartment in the retention test, 639 
indicating preserved cognitive function but there was no effect of UE2316 (by two-way ANOVA 640 
training vs retention effect p<0.001, drug effect p=0.26; by Student’s t-test *p=0.03, ***p=0.0007). B: 641 
Passive avoidance was retested after 41 weeks of treatment with vehicle (n=13) or UE2316 (n=23) in 642 
chow. UE2316 but not vehicle treated mice demonstrated a significant increase in latency to enter the 643 
dark compartment in the retention test (by Student’s t-test **p=0.004). 644 
Figure 5. Behavior of Tg2576 mice following long term administration of UE2316. A: Open field 645 
was performed in control (vehicle: n=5, UE2316: n=5) and Tg2576 mice (vehicle: n=13, UE2316: 646 
n=23) after 38 weeks of treatment with either normal chow or diet containing UE2316.  The Tg2576 647 
mice spent more time in the inner zone than their wild type counterparts; however, there was no effect 648 
of drug administration (by two-way ANOVA, *p<0.05). B: Spontaneous alternation was assessed in 649 
Tg2576 mice after 39 weeks of vehicle (n=13) or UE2316 treatment (n=23). UE2316-treated mice 650 
exhibited a significant increase in percent alternation compared to control mice (by Student’s t-test 651 
*p=0.04). C: The spatial Morris Water Maze test was performed after 52 weeks of treatment. Mice 652 
that were able to find the platform in a visible platform test were tested in their ability to find the 653 
submerged platform using spatial cues located around the testing room. UE2316 treated mice (n=9) 654 
exhibited significant decreases in latency to find the hidden platform across the testing period 655 
compared to vehicle treated animals (n=6) (2-way repeated measures ANOVA, drug effect p=0.02 656 
and interaction of drug with time p<0.01; by Student’s t-tests *p<0.05 at days 3, 5 and 6). 657 
Figure 6: Effect of short- and long-term UE2316 administration on amyloid plaque burden in 658 
Tg2576 mice. A: Short term plaque number. 6E10 positive amyloid plaques were counted in at least 5 659 
non-sequential sections per mouse treated for 29 days with vehicle or UE2316 (n=10 per treatment) 660 
via SC minipumps using the KS300 imaging program and the total number of positive plaques was 661 
expressed per area of the brain. UE2316 had no effect on plaque number in the hippocampus but 662 
decreased 6E10 staining in the cortices (Student’s t-test, **p=0.002), amygdala (Student’s t-test, 663 
*p=0.05) and whole brain (Student’s t-test, *p=0.01) in comparison to vehicle. B: Short term plaque 664 
area. Total plaque area of short term (29 day) treated mice was measured using the KS300 imaging 665 
program and was expressed as plaque area divided by the total area of the brain region in question. 666 
The total plaque area in the cortex was decreased by UE2316 in comparison to vehicle (Student’s t-667 
test, ***p=0.0001). C: Long term plaque number. 6E10 positive amyloid plaques were counted in at 668 
least 5 non-sequential sections per mouse treated for 44 weeks with vehicle or UE2316 (n=5 per 669 
treatment) in the diet using the KS300 imaging program and the total number of positive plaques was 670 
expressed per area of the brain. UE2316 had no statistically significant effect on plaque number in the 671 
hippocampus or cortex in comparison to vehicle. 672 
Figure 7: Effects on brain pathology in Tg2576 mice treated with UE2316. A: Representative 673 
brain sections from Tg2576 mouse showing amyloid plaques in brain regions stained with 6E10 674 
antibody. (a) cortex, vehicle treated (b) cortex, UE2316-treated (c) amygdala, vehicle-treated (d) 675 
amygdala, UE2316-treated (e) hippocampus, vehicle-treated (f) hippocampus, UE2316-treated. B: 676 
Representative western blot of cortex protein (30µg/sample) from 29 day treated mice. Quantitation 677 
was performed using the Odyssey Infrared imaging system and adjusted for beta-tubulin. IDE levels 678 
were increased in UE2316 treated cortices compared to vehicle treated tissues in both wild type and 679 
Tg2576 animals (see Table 1). 680 
 681 
Supplementary Data. 682 
Supplementary Figure 1: Effects of short-term (29 day) treatment with UE2316 in wild type and 683 
Tg2576 mice on food intake and body weight. Wild-type and Tg2576 mice were treated via 2 684 
subcutaneously implanted Alzet minipumps with either vehicle or 10 mg/kg/day UE2316 for 29 days 685 
(n=10 per treatment). A: Body weights were measured weekly in all mice. There was no effect of 686 
UE2316 on body weight although the Tg2576 mice weighed less than the controls (two-way repeated 687 
measures ANOVA, genotype effect p<0.001 and interaction with time p=0.001). B: Food was 688 
weighed weekly in all mice. Food intake was averaged as grams of food consumed/day. Tg2576 mice 689 
consumed more food but there was no effect of UE2316 (two-way repeated measures ANOVA 690 
genotype effect p=0.004). 691 
 692 
Supplementary Figure 2: Effects on food intake and body weight with long-term inhibition of 693 
11β-HSD1 in Tg2576 mice by UE2316 supplemented diet. A: Estimated daily drug dosage was 694 
calculated weekly by measuring the food intake and comparing with body weight. The dose of 695 
UE2316 remained constant throughout the experiment. B: Individually housed mice treated with 696 
either control diet (RM1; n=16) or RM1 diet supplemented with 175 ppm UE2316 (RM1 + UE2316; 697 
n=32) were weighed weekly. 5 animals per group were culled after 45 weeks and the remainder 698 
continued until 57 weeks. By repeated measures ANOVA, there was an interaction of drug treatment 699 
with time only before 45 weeks (p<0.01) with UE2316 treated animals tending to be lighter in the 700 
early weeks of the study. C: Food intake was measured weekly in both groups and was averaged as 701 
grams of food/day. Food intake was higher in mice fed diet supplemented with UE2316 in the first 702 
few weeks of the study (by repeated measures ANOVA, drug interaction with time p<0.001; by 703 
Student’s t-test *p<0.05 at week 10).  704 
Supplementary Figure 3: Effects on behavior and brain pathology in Tg2576 mice treated with 705 
UE2316. The water maze probe test was performed 24 hours after the final spatial water maze trial. 706 
UE2316-treated Tg2576 mice (n=9) spent significantly more time exploring the target quadrant of the 707 
water maze than the vehicle treated mice (n=6) (*p=0.02). 708 
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